(c) The details of energy consumption in respect of some of the fertiliser plants based on these technologies are given below:

Name of the plants	Energy Consumption Million K cal per tonne of Ammonia	
	1989-90	1990 91
1	2	3
RCF, Thal (Topsoe)	9.92	9.6
KRIBHCO, Hazira (Kellong) . . .	8.61	8.7
NFL, Vijaipur (Topsoe)	8.08	8.1
IFFCO, Aonla (Topsoe)	8.19	8.0

Filing writ petitions by drug company

3051. SHRIMATI KAILASHPATI: Will the PRIME MINSTER be pleased to state:

(a) whtther it is a fact that number of drup companies have filed writ petitions in various courts against the action of Government;

(b) names of the companies who filed writ petitions, details of courts and issues on which petitions were filed;

(c) how many writ petitions are pending and since when;

(d) whether it is a fact that in number of cases, Government have not even filed affidavits:

(e) if so, details of those cases and reasons for delay;

(f) whether it is a fact that Government have still to submit replies in these cases;

(g) if so, the details of these cases;

(h) since when the cases of Synbiotics relating to Streptomycin and Fulford relating to Gentamycin are pending and what is the present position in each case; and

(i) what steps have been taken to expedite the matters?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) to (g) The position is explained below:

S.No.	Name of the High Court	Name of the Company	Present Position
1		2	3
(i)	*Delhi High Court* . . .	(1) M/s. Synbiotics	Pending
		(2) M/s. Fulford	Pending
		(3) M/s. Glaxo	Listed for Hearing
(ii)	*Bombay High Court* . .	(1) M/s. Hoechst (2) M/s. Burroughs Wellcome (3) M/s. Nicholas	The Hon'ble Court has directed that the Companies be given a hearing and a speaking order passed. The Writ Peitions have been treated as withdrawn.

1	2	3
	(4) M/s. Lyka Labs.	Pending
	(5) M/s. Merind	Pending
(iii) *Calcutta High Court*	(1) M/s. Carews	Pending
	(2) M/s. Dolphin	Pending
(iv) *Ahmedabad High Court*	(1) M/s. Cadila	Pending

The Writ Petitions are mainly against the prices fixed by the Govt. and/or notice for recovery of the tentative liability of the Company, issued by the Govt. The Counter-affidavits have yet to be filed by the Govt. in the case of M|s. Lika Labs., M/s. Merind, M|s. Dolphin and M(s. Cadila and these are being expedited.

(h) and (i) The matter is being pursued.

Price of Flucort Range formulations

3052. SHRIMATI RATAN KUMARI: Will the PRIME MINISTER be pleased to state:

(a) whether it is a fact that contrary to the Government decision price of Flucort Range of formulations has been increased by using a small scale sector unit as an intermediary;

(b) if so, the name of the small scale unit and the percentage of price increase in each pack and strength;

(c) what is the price being charged on Flucort range of finished medicines based on the stocks with chemists and since when price increase has been put into effect;

(d) whether it is a fact that new price amounts to over-charging the consumer by rupees four crores per annum; and

(e) what steps Government have taken to pass orders for seizure of stock and prosecution of the management for open de finance?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) and (b) No such instance has come to the notice of Government.

(c) to (e) The State Drugs Controller has been asked to verify as to when the company had implemented the prices fixed by the Government in respect of Flucort range of formulations.

Indication for using Glipizide

3053. SHRI ANANT RAM JAISWAL: Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 1669 given in the Rajya Sabha on the 12th September, 1991 and state:

(a) what is the indication for which Glipizide is used;

(b) what are the names of the producers of Glipizide and what was the production of each during the last three years year-wise;

(c) whether it is also a fact that Glipizide is under price control;

(d) whether it is also a fact that Glybenclamide is also used for same indication;

(e) if so, on what basis this drug has been decontrolled and what are the criteria adopted;

(f) whether it is also a fact that Pentoxyphylline is outside price control;

(g) if so, on what basis;

(h) what are the names of drugs of this producer which are outside price control and what are the names of other producers of these drugs; and

(i) what was the production of each including the producer in question during the last three years, year-wise?